Once a month, we screen the Europe-listed stocks under Morningstar’s coverage for newly overvalued names—those whose prices have just climbed into ranges warranting 1- or 2-star Morningstar Ratings. Over the past month, eight stocks saw their ratings change to 2 stars, while none joined the four Europe-listed names in 1-star territory.
The five new 2-star European stocks with the largest market capitalization are:
The full list of new 2-star stocks can be found at the bottom of this story. All returns in this article are reported in the stock’s base currency and all data is sourced from Morningstar Direct.
What Is the Morningstar Rating for Stocks?
The Morningstar Rating can help investors identify stocks that are truly undervalued or overvalued, cutting through the market noise. The rating is determined by three factors: a stock’s price, its fair value estimate—Morningstar’s estimate of its intrinsic worth—and its Uncertainty Rating, which captures the range of potential outcomes for that estimate. Stocks rated 4 or 5 stars are considered undervalued, those rated 3 stars are fairly valued, and the ones rated 1 or 2 stars are considered overvalued.
The Latest Stock Valuation Changes
The Morningstar Europe Index fell 0.63% over the past month as of Oct. 13, leaving the overall European stock market moderately undervalued, hovering at a 10% discount to its fair value estimate on a market cap-weighted basis.
Of the 321 Europe-listed stocks covered by Morningstar analysts:
- 40% are undervalued, 45% are fairly valued, and 16% are overvalued.
- 20 are newly undervalued.
- Eight are newly overvalued.
- Zero moved from a 2-star rating to a 1-star rating.
- One moved from a 1-star rating to a 2-star rating.
- Among the newly overvalued stocks, zero jumped from a 3-star rating to a 1-star rating.
- 20 are no longer overvalued.
Metrics for This Month’s New 2-Star Stocks
Novartis NOVN
- Morningstar Rating: ★★
- Fair Value: CHF 105
- Uncertainty Rating: Medium
Drug manufacturer Novartis climbed 6.48% over the past month, bumping its Morningstar Rating to 2 stars from 3. The company’s stock is down 4.24% over the past three months and is up 17.62% over the past year. The stock’s price is 14% above its fair value estimate of CHF 105, with an Uncertainty Rating of Medium. The large-core stock has a wide economic moat.
Givaudan GIVN
- Morningstar Rating: ★★
- Fair Value: CHF 3,500
- Uncertainty Rating: Low
Specialty chemicals company Givaudan gained 20.64% over the past month, shifting its Morningstar Rating to 2 stars from 4. Givaudan has climbed 11.61% over the past three months and 16.44% over the past year. The stock is trading at a 9% premium to its fair value estimate of CHF 3,500, with an Uncertainty Rating of Low. Givaudan is a large-core company with a wide economic moat.
Sandoz SDZ
- Morningstar Rating: ★★
- Fair Value: CHF 60
- Uncertainty Rating: High
Following a 7.34% gain over the past month, drug manufacturer Sandoz saw its Morningstar Rating move to 2 stars from 3. Sandoz has gained 7.47% over the past three months and 48.09% over the past year. The large-growth stock has no economic moat. Sandoz is trading at a 19% premium to its fair value estimate of CHF 60, with an Uncertainty Rating of High.
Wärtsilä WRT1V
- Morningstar Rating: ★★
- Fair Value: EUR 27
- Uncertainty Rating: Medium
Specialty industrial machinery firm Wärtsilä gained 4.09% over the past month, shifting its Morningstar Rating to 2 stars from 3. Wärtsilä has climbed 0.34% over the past three months and 17.04% over the past year. The stock is trading at a 10% premium to its fair value estimate of EUR 27, with an Uncertainty Rating of Medium. Wärtsilä is a large-growth company with a wide economic moat.
Sonova SOON
- Morningstar Rating: ★★
- Fair Value: CHF 223
- Uncertainty Rating: Medium
Medical devices company Sonova climbed 18.04% over the past month, bumping its Morningstar Rating to 2 stars from 3. The company’s stock is up 29.49% over the past three months and 25.28% over the past year. The stock’s price is 20% above its fair value estimate of CHF 223, with an Uncertainty Rating of Medium. The mid-growth stock has a narrow economic moat.

